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Whole genome sequencing (WGS) offers the potential to predict antimicrobial susceptibility from a
single assay. The European Committee on Antimicrobial Susceptibility Testing established a subcom-
mittee to review the current development status of WGS for bacterial antimicrobial susceptibility testing
(AST).
The published evidence for using WGS as a tool to infer antimicrobial susceptibility accurately is
currently either poor or non-existent and the evidence / knowledge base requires signiﬁcant expansion.
The primary comparators for assessing genotypicephenotypic concordance from WGS data should be
changed to epidemiological cut-off values in order to improve differentiation of wild-type from non-
wild-type isolates (harbouring an acquired resistance). Clinical breakpoints should be a secondary
comparator. This assessment will reveal whether genetic predictions could also be used to guide clinical
decision making. Internationally agreed principles and quality control (QC) metrics will facilitate early
harmonization of analytical approaches and interpretive criteria for WGS-based predictive AST. Only data
sets that pass agreed QC metrics should be used in AST predictions. Minimum performance standards
should exist and comparative accuracies across different WGS laboratories and processes should be
measured. To facilitate comparisons, a single public database of all known resistance loci should be
established, regularly updated and strictly curated using minimum standards for the inclusion ofal Resistance and Healthcare Associated Infections (AMRHAI) Reference Unit, National Infection Service, Public Health
.
odford).
rst authors.
evier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. All rights reserved.
M.J. Ellington et al. / Clinical Microbiology and Infection 23 (2017) 2e22 3resistance loci. For most bacterial species the major limitations to widespread adoption for WGS-based
AST in clinical laboratories remain the current high-cost and limited speed of inferring antimicrobial
susceptibility from WGS data as well as the dependency on previous culture because analysis directly on
specimens remains challenging.
For most bacterial species there is currently insufﬁcient evidence to support the use of WGS-inferred
AST to guide clinical decision making. WGS-AST should be a funding priority if it is to become a rival to
phenotypic AST. This report will be updated as the available evidence increases. M.J. Ellington, CMI
2017;23:2
Crown Copyright © 2016 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology
and Infectious Diseases. All rights reserved.Introduction
The remit of the European Committee on Antimicrobial Sus-
ceptibility Testing (EUCAST) Subcommittee on the Role of Whole
Genome Sequencing (WGS) in Antimicrobial Susceptibility Testing
of Bacteria was:
(a) to perform a review of the literature describing the role of
WGS in antimicrobial susceptibility testing (AST) of bacteria;
(b) to assess the sensitivity and speciﬁcity of WGS compared
with standard phenotypic AST;
(c) to consider how WGS for AST may be applied in clinical
microbiology laboratories and the likely implications for
phenotypic and other genotypic methods in use;
(d) to consider the epidemiological implications of using WGS;
(e) to consider the clinical implications of WGS for the selection
of antimicrobial therapy;
(f) to consider the principles of how the results of WGS for AST
could be presented to clinical users;
(g) to describe the drivers and barriers to routine use of WGS;
(h) to report at ECCMID 2016.
We chose to tackle this task on a ‘by organism’ basis
(for Enterobacteriaceae (non-Salmonellae); Salmonella spp.;
Staphylococcus aureus; Streptococcus pneumoniae; Neisseria gon-
orrhoeae; Mycobacterium tuberculosis; Clostridium difﬁcile; Aci-
netobacter baumannii and Pseudomonas aeruginosa), with
particular focus on the use of technology for characterizing
cultured isolates of bacteria that have been identiﬁed as critical
antimicrobial resistance (AMR) threats by the World Health Or-
ganization [1]. There are encouraging signs, but our report makes
clear that more robust data are needed across these diverse ‘bug/
drug’ combinations. Furthermore, work is needed to overcome
problems currently posed by particular species and/or certain
antimicrobial classes. We highlight these gaps, make recom-
mendations (summarized below), and encourage others to use
these to generate the analyses that will move this important
topic forwards.
The committee met by teleconference between July 2015 and
March 2016 to agree the organisms and detailed scope of the
report and appoint specialists to undertake non-systematic re-
views of the literature and write the corresponding sections of
the report. The ﬁndings of the report were agreed via telecon-
ference and/or email, and were presented at the 26th European
Congress on Clinical Microbiology and Infectious Diseases (ECC-
MID) in April 2016. Shortly after that, a draft for public consul-
tation was posted online (at www.eucast.org/documents/
consultations). The Subcommittee considered and responded to
comments and several were included in or affected the content of
this print version.Summary of the conclusions and recommendations
(a) For most bacteria considered in this report, the available
evidence for using WGS as a tool to infer antimicrobial sus-
ceptibility (i.e. to rule-in as well as to rule-out resistance)
accurately is either poor or non-existent. More focused
studies and additional funding resources are needed as a
priority to improve knowledge.
(b) The primary comparator for WGS-based prediction of anti-
microbial susceptibility should, whenever possible, be the
epidemiological cut-off value (ECOFF).
(c) Assessing genotypic data against clinical breakpoints repre-
sents a tougher challenge, but will be necessary if WGS-
based testing is to guide clinical decision making. Clinical
breakpoints should therefore be used as a secondary
comparator, ideally using the same data sets as used for
ECOFF-based assessments.
(d) Most published evidence does not currently support use of
WGS-inferred susceptibility to guide clinical decision
making (i.e. to replace routine phenotypic AST in most or
all cases).
(e) There should be international agreement on the most
appropriate and effective principles and quality control (QC)
metrics to facilitate early standardization and harmonization
of analytical approaches and interpretative criteria for WGS-
based predictive AST. Only data sets passing agreed QC
metrics should be used in antimicrobial susceptibility pre-
dictions, as resistance genes or mutations might bemissed in
sequences of poor quality.
(f) Different bioinformatics tools for predicting AST should
perform tominimum standards and should be calibrated and
shown to be equivalent in terms of the results generated.
(g) A single database of all known resistance genes/mutations
should be established to ensure that there is parity of anal-
ysis and to facilitate measurement of comparative accuracies
across different systems and bioinformatics tools. This
database should be updated regularly, and must have strictly
curated minimum standards for the inclusion of new resis-
tance genes and mutations. An important function of a
centralized database would be to control resistance gene
nomenclature.
(h) Expansion of the evidence base is a critical priority if WGS is
to be considered seriously as a rival to phenotypic AST.
(i) For most bacterial species and in most countries the current
cost and speed of inferring antimicrobial susceptibility from
WGS data remain prohibitive to wide adoption in routine
clinical laboratories.
(j) This report should be considered as a baseline discussion
document, which should be revisited and updated at regular
intervals (likely every 18e24 months) as sequencing
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Deﬁning resistance
MIC distributions of wild-type bacteria, ECOFFs and their
relationship to clinical breakpoints
In 2002, EUCAST introduced the concept of gathering large
numbers of MIC values frommany contributors to present on aweb
site as aggregated reference MIC distributions for every important
combination of microorganisms and antimicrobial agents [2]. The
original conditions of acceptance of individual MIC distributions
were:
(a) that each contribution of MIC values must consist of a min-
imum number of isolates;
(b) that the species was well deﬁned;
(c) that MIC determinations were performed using standardized
methodology (or a method calibrated to a standardized
method);
(d) that the concentrations tested were not truncated at the
lower end of the concentration series.
A EUCAST Subcommittee is currently reviewing the rules for
inclusion and exclusion of data sets in aggregatedMIC distributions
and the process by which ECOFF values are deﬁned.
Contributors of MIC data are not informed about whether or not
their contributions are accepted. There are currently more than 29
000 MIC distributions in the EUCAST database, which amounts to
many millions of MIC values. The distributions are from breakpoint
committees, individual researchers in human and veterinary
medicine, programmes for the surveillance of AMR in humans and
animals, EUCAST development projects, pharmaceutical companies
as part of programmes for the development of new agents, and
more. The distributions are freely available on www.eucast.org.Fig. 1. Cefotaxime MIC distribution for Escherichia coA typical aggregated MIC distribution, in this case for Escherichia
coli and cefotaxime, is shown in Fig. 1. Of 72 cefotaxime MIC dis-
tributions for E. coli available in the database, 41 fulﬁlled the criteria
for acceptance, were aggregated and the aggregated distribution
displayed on the EUCAST web site as in Fig. 1.
MIC distributions are uni-modal or multi-modal. The left-hand,
most often dominating and Gaussian-shaped part of the distribu-
tion, represents the isolates devoid of phenotypically detectable
acquired resistance mechanisms, otherwise known as ‘the wild-
type (WT) MIC distribution’. Furthermore, MIC values for bacteria
from humans and animals are distributed in the same way. TheWT
is not affected by the geographical location where the isolates are
collected, the specimen source (e.g. humans or animals [3], or
healthy or sick individuals) or the era of collection (some of the
distributions date from the 1950s whereas others are very recent).
There are several ways (biological or statistical) to assess the WT
distribution to deﬁne the MIC value best representing the upper
end of theWT distribution [4e6]. Despite the fact that there is often
no absolute and distinguishing threshold to mark the upper end of
the WT or beginning of the non-wild-type (NWT) distribution, it
has been useful to deﬁne the ECOFF as the ‘highest MIC for or-
ganisms devoid of phenotypically detectable acquired resistance
mechanisms’. It provides a means to distinguish between resistant
and susceptible populations in a biological sense.
From a clinical point of view, categorizing isolates into WT and
NWT informs the clinician of whether or not the isolate causing
infection is devoid of acquired resistance mechanisms or not,
irrespective of its clinical susceptibility categorization as suscepti-
ble (S), intermediate (I) or resistant (R).
There is no immediate relationship between the categorization
of WT and NWT on one side and the clinical categorization ‘S’, ‘I’
and ‘R’ on the other. AWT microorganism can be categorized as ‘S’,
‘I’ or ‘R’ to a particular antimicrobial agent and a NWT organism
may still be categorized as ‘S’. This means that if one wants to
encompass bothWTand NWTon one hand and clinical ‘S’, ‘I’ and ‘R’
on the other, the possible susceptibility categories for an isolate toli (n ¼ 10 397 from 41 aggregated distributions).
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There are many examples of each of these categories in the EUCAST
breakpoint tables. An E. coli isolate with a ciproﬂoxacin MIC of
0.25 mg/L exempliﬁes the SNWT category. Conversely, Pseudomonas
aeruginosa and tigecycline or Stenotrophomonas maltophilia and
carbapenems both exemplify the RWTcategory. For ampicillin, TEM-
1-producing E. coli represents RNWT.
At the outset of the review of all breakpoints for all antimicrobial
classes in 2002, EUCAST decided that clinical breakpoints should
not divide WT MIC distributions. If breakpoints are allowed to
bisectWTMIC (or zone diameter) distributions, themethodological
variation would obviate reproducible ‘S’, ‘I’ and ‘R’ categorization
[2], despite increased standardization of MIC determination [7]. We
have not had reason to change this view. Following on from this,
once it has been established that the species is a good clinical target
for the agent in question, the ECOFF is the lowest possible sus-
ceptible breakpoint. The ECOFF is also the relevant ‘cut-off’ to
screen for low-level resistance using phenotypic susceptibility
testing.
ECOFFs provide an opportunity to compare AMR and resistance
development when clinical breakpoints: (a) differ among com-
mittees and agencies, e.g. EUCAST, CLSI, US Food and Drug
Administration and European Medicines Agency; (b) change over
time; or (c) differ between humans and animals. There is no dif-
ference in principle between MIC distributions and ECOFFs for fast-
growing non-fastidious and fastidious bacteria, and those for slow-
growing bacteria, such as Mycobacterium tuberculosis [8], or fungi,
such as Candida spp. and Aspergillus spp. [9].
More information on EUCAST in general and wild-type MIC
distributions and ECOFFs in particular can be obtained from the
EUCAST website (www.eucast.org) and the recently published re-
view of EUCAST activities since 2001 [10].
This Subcommittee sought to assess whether available data are
sufﬁcient to test the hypothesis that the closest relationship be-
tween sequencing and phenotypic testing will be achieved by using
the WT versus NWT categories.
Molecular mechanisms of antimicrobial resistance
For most of the clinically relevant bacterial pathogens, pheno-
typic analysis of bacterial susceptibility to antimicrobial agents is
relatively straightforward and relies on well-proven methods, such
as agar and broth microdilution (the latter being the reference
standard) or disc diffusion, followed by interpretation according to
agreed guidelines.
With the introduction of Sanger sequencing in the mid-1970s
and PCR in the 1980s, it became possible to study some of the
molecular mechanisms responsible for the observed non-
susceptibility to various antimicrobial agents. Common examples
of these molecular mechanisms are: (a) transferable AMR genes
(e.g. extended-spectrum b-lactamases (ESBLs)); (b) upregulation of
AMR gene expression by point mutations (e.g. ampC in E. coli or
regulatory mutations effecting efﬂux in many taxa); (c) porin
modiﬁcation or loss (e.g. by deletion events and/or lack of expres-
sion); (d) point mutations in essential single-copy (e.g. gyrA and/or
parC of Enterobacteriaceae) andmulti-copy (e.g. mutations in one or
more loci of the 23S rRNA gene) housekeeping genes. To complicate
the matter, some bacterial species (or higher taxonomic orders) can
be intrinsically resistant to a given antimicrobial agent [11]. This
intrinsic resistance can be caused by some of themechanisms listed
above but can also be a result of the lack or unavailability of targets
for the antimicrobial agent.
Traditional Sanger sequencing and rapid molecular methods,
e.g. PCR, allow screening for a limited number of resistance genes,
which are often selected because they confer resistance to keyantibiotics (e.g. genes encoding ESBLs or carbapenemases). The
data offer very limited opportunities to compare genotype with
phenotype. By contrast, WGS has potential to yield data about any
resistance gene or mutation present and the data might therefore
be analysed to create a genotypically inferred antimicrobial resis-
tance proﬁle (or antibiogram) or, perhaps, to infer susceptibility.
Using next-generation sequencing data for in silico
(genotypic) detection of AMR
Next-generation sequencing data producing WGS information
can originate from a variety of different sequencing platforms. A
review of these technologies is beyond the scope of this report, but
can be found elsewhere [12]. Short read (e.g. 100 to 500 bp) output
with high accuracy may be complemented by that produced by
much longer reads. At the time of writing, these newer platforms
come at signiﬁcantly greater cost and higher error rates than the
short-read technology. The dominant short-read technology pro-
duces single (raw) reads that are in most cases shorter than the
gene(s) responsible for the reduced susceptibility to a given anti-
microbial agent and either need to undergo de novo assembly to
obtain larger fragments of the originally contiguous DNA (‘contigs’)
or by reference (‘mapping’) to known genetic targets (in this case,
AMR genetic determinants). Repeat regions in DNA fragments are
particularly challenging and correct assembly may be problematic.
Using WGS data for detection of the many different molecular
mechanisms leading to AMR yields far more information from a
single physical test than other methods (e.g. PCR or microarrays)
and, at its most fundamental level, does not require previous
knowledge of the resistance phenotype of the isolate. Nevertheless,
there is a need to understand the potential ‘added value’ of WGS
with regard to the clinical implications of AMR and so the validity of
data generated by these novel technologies must be challenged
against phenotypic methods to differentiateWT isolates fromNWT,
or S isolates from R isolates. In this regardWGS is a genetic test that
deﬁnes a genotype asWTor NWTand compares most directly with
phenotypic criteria that do the same (ECOFFs).
Although more informative than conventional molecular tech-
niques, WGS is no simple task, especially when the data have been
generated by short-read (‘second generation’) technology. Detec-
tion of deﬁned resistance genes can be achieved either by BLAST
(Basic Local Alignment Search Tool) analysis of draft genomes to-
wards a gene-based database or bymapping individual reads to the
same type of database. Such solutions are already available as either
downloadable tools, such as ARG-ANNOT [13], or web-based tools,
such as RESFINDER for BLAST analysis and MGMAPPER for mapping of
reads [14,15]. The gene-based solutions have the obvious require-
ment for full-length genes identical to already characterized (and
preferably published) AMR genes. The bioinformatics solutions
mentioned above are able to identify less-than-perfect hits (<100%
nucleotide identity, truncated genes because of non-perfect de novo
assembly), but such hits will always need to be subjected to some
sort of assessment if they are to be translated into a predicted
phenotype.
Accurate prediction of resistance by WGS can be complicated by
insufﬁcient knowledge about all genetic variation leading to
reduced susceptibility for a given antimicrobial agent (such as
colistin or daptomycin) as well as the emergence of new mecha-
nisms and when resistance arises due to altered expression of
intrinsic genes (e.g. those encoding efﬂux pumps). Also, shortcom-
ings of second-generation sequencing technology may hamper ac-
curacy. An example of the latter could be Enterococcus faecium,
where a point mutation (G2576T) in two or three copies of the six
23S rRNA loci would lead to phenotypic resistance to linezolid [16].
De novo assembly of second-generation sequence data from the
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the 23S gene due to the consensual nature of the assemblers, where
only the most abundant base is reported in the draft genome data.
Quality metrics for WGS
Like any other test, the quality of WGS data can vary between
individual test runs. Therefore before any actual bioinformatics
analysis, QC steps are essential to assess whether the WGS data
have reached a suitable standard. Only data sets passing these QC
metrics should be used in antimicrobial susceptibility predictions,
as resistance genes or mutations might be missed in sequences of
poor quality. These QC steps include (a) assessing the quality and
quantity of the raw reads to ensure sufﬁcient coverage (e.g. >30
times coverage) of the bacterial genome, (b) assessing the quality of
the de novo assembly (leading to a draft genome sequence) and (c)
detecting possible contaminant DNA, originating either from up-
stream handling of the bacterial isolates and DNA puriﬁcation or
from the preparation and running of the DNA samples on the
sequencer. Some of the different sequence QC parameters that have
been used are listed in Table 1. The parameters most frequently
used are highlighted in bold. There are currently no international
standards for QC thresholds to use for assessing quality. This seems
to be individually decided by researchers and may also depend on
the purpose of the study or the methods used for sequencing. A
high error rate for a sequencing method can be compensated to
some extent by greater depth of coverage. The necessary QC
threshold also depends on the species analysed. Hence, beforeWGS
can be routinely implemented into accredited clinical practice
there is a need to establish necessary minimum QC thresholds (e.g.Table 1
Selected quality control (QC) parameters used to evaluate whole genome sequencing (W
QC parameter Explanation
Number of reads Number of reads
Average read length The average leng
Number of reads mapped to reference sequence The number of re
Proportion of reads mapped to reference sequence (%) The proportion o
Number of reads mapped to reference chromosome The number of re
Proportion of reads mapped to reference chromosome (%) The proportion o
exceed 100%.
Reads mapped to reference plasmids The number of re
Proportion of reads mapped to reference plasmids (%) The proportion of
100%.
Depth of coverage, total DNA sequence Describes the num
pairs sequenced d
(same strain), oft
Depth of coverage: chromosome As for total DNA c
of the closed chro
Depth of coverage: plasmid As for total DNA c
of the closed plas
Size of assembled genome Often used to ide
that expected it c
Size of assembled genome per total size of DNA sequence (%) The proportion o
100%.
Total number of contigs Generally, the tot
organisms with g
Number of contigs >500 bp The total number
well to the total n
Longest contig length The length of the
Shortest contig length The length of the
Mean, median and standard deviation Mean, median an
N50 The length for wh
sum of the length
also contains at l
good quality, but
NG50 Helpful for compa
the NG50 length
N50.by multiple sequencing of reference isolates) for identiﬁcation of
resistance genes and their variants.
The Global Microbial Identiﬁer initiative [15] is currently
collaborating with the US Food and Drug Administration and the
COMPARE project [16] in proﬁciency testing of WGS data, and
isolates have been distributed to 50 laboratories worldwide. This
and similar initiatives are important ﬁrst steps towards setting
objective QC thresholds. There is, however, a need to expand this
using more isolates as well as developing standard data sets of raw
sequences to facilitate the assessment of performances across
different laboratories.
The need for a standardized, open-access database
Most of the genomes released now are not closed, so there is a
need for better standardization of annotation to facilitate detection
of AMR genes because standard BLAST analysis will retrieve plenty
of hits within annotated or raw sequences available in GenBank,
and those hits will be inconsistently annotated even where the
actual sequences are identical.
Currently several AMR databases exist, and they are either
downloadable for use locally (e.g. ARG-ANNOT) [13] or are web-
based solutions (RESFINDER for BLAST analysis and MGMAPPER for
mapping of reads [14,15] and a Comprehensive Antibiotic Research
Database, CARD [17]). In addition to a fully curated database of
accurately annotated genes that seeks to avoid the pitfalls posed by
erroneously annotated genes, there also exists a need for a single,
standardized ‘challenge database’ solution that contains all vali-
dated AMR genes as well as those point mutations in chromosomal
target genes that are known to be associated with antimicrobialGS) data (most commonly used are shown in bold)
refers to sequence yield (the amount sequenced)
th of all reads, measured in base pairs.
ads that map to a closed (ﬁnished) genome (same strain).
f reads that map to a closed genome (same strain).
ads that map to a closed chromosome (same strain).
f reads that map to a closed genome’s chromosome (same strain). This cannot
ads that map to plasmids, if present.
reads that map to plasmids (if present) of the closed genomes. This cannot exceed
ber of times the sequenced base pairs cover the reference DNA. Number of base
ivided by the total size (both chromosome and plasmids) of the closed genome
en expressed with an “x” (e.g. 30x). A minimum depth of 30x is usually preferred.
overage, but describes the number of base pairs sequenced divided by the total size
mosome (same strain).
overage, but describes the number of base pairs sequenced divided by the total size
mid (same strain).
ntify contamination. If the calculated size of all the contigs in base pairs exceeds
ould indicate more than one genome.
f contigs that map directly to the closed genome (same strain). This cannot exceed
al number of contigs assembled, <1000 contigs indicates good quality. For
enomes 5e6 Mb in size then <100 contigs is (generally) realistic.
of contigs assembled that have a sequence length >500 bp. This should correspond
umber of contigs.
longest contig.
shortest contig
d standard deviation of the contigs, used to evaluate quality.
ich the collection of all contigs of that length or longer contains at least half of the
s of all contigs, and for which the collection of all contigs of that length or shorter
east half of the sum of the lengths of all contigs. N50 >15 000 normally indicates
minimum size of 30 000 bp is often preferred.
risons between assemblies. As N50, except that 50% of the genome size must be of
or longer. Where the assembly size  the genome size then NG50 cannot exceed
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different bioinformatics analysis tools. Any such solution should be
ﬂexible so that stringency of detection can be changed to allow
detection from partial gene sequences (length <100%) and/or AMR
genes with identities <100%. Looking at conserved sequence motifs
in gene families (e.g. b-lactamases) should also help in assessing
the validity of newly detected genes and in particular those
exhibiting low sequence identity matches.
This single web solution should be iterative and enhanced by
regular, validated updates of newly identiﬁed gene sequences and
point mutations at a frequency that remains to be decided. Machine
learning should be explored to improve iteratively and automati-
cally the detection algorithms for this purpose.
However, to achieve this goal there must also be clear interna-
tional consensus on the criteria used to deﬁne a gene as ‘new’ (i.e. %
of identity with existing genes) or as a variant of known genes. This
is inextricably linked to issues of gene nomenclature. Currently,
different criteria are used depending on the antimicrobial class to
which a particular gene confers resistance. For example, a ‘new’ b-
lactamase gene can be deﬁned by as little as one amino acid dif-
ference from a known sequence and regardless of any impact that
this change might have on the conferred resistance phenotype.
There should be minimum standards for inclusion of new
resistance determinants in the standardized database, and these
standards would probably differ from those currently required for
publication (e.g. they may be more demanding). It seems reason-
able that new genes should have a full gene sequence, which can be
translated into a protein sequence, and that they should have been
unequivocally linked to a predicted resistance phenotype, as was
recently exempliﬁed bymcr-1 plasmid-mediated colistin resistance
[18], before being added to the database.
Categories of systematic errors in WGS predictions of AMR
When comparing the concordance between phenotypic and
genotypic AMR it is essential to consider the reasons that errors
may occur. Three broad reasons for systematic errors are:
(a) An inadequate limit of detection of WGS.
(b) Flaws with phenotypic AST.
(c) Incomplete understanding of the genotypic basis of pheno-
typic resistance.
Of these, the limit of detection ofWGS applies to the detection of
hetero-resistance, which is most applicable to Mycobacterium
tuberculosis, as for most other organisms WGS is usually performed
from single bacterial colonies. Flaws due to phenotypic detection
issues become most apparent when the knowledge base of the
genetic basis of resistance is relatively complete for a given organ-
ism and can point to such problems. For the purposes of this report
it will likely only apply to well-progressed / well-characterized
species (such as Mycobacterium tuberculosis and Staphylococcus
aureus). At this relatively early stage of development of WGS-based
genotypeephenotype comparisons it can be anticipated that there
may bemany gaps in the knowledge base and thesewill be explored
and highlighted in the following evidence reports.
Evidence reports for in silico prediction of antimicrobial
resistance
Enterobacteriaceae (other than Salmonella spp.)
Background
Multidrug-resistant Enterobacteriaceae are emerging as a serious
infectious disease challenge. They can accumulatemany antimicrobialresistance genes through horizontal transfer of genetic elements,
those coding for b-lactamases (e.g. ESBLs and carbapenemases), ﬂu-
oroquinolones and aminoglycosides being of particular concern.
Published studies
A small number of studies have assessed the feasibility of using
WGS to infer AMR in E. coli and Klebsiella pneumoniae genomes;
they are largely based on screening for known acquired AMR genes
and a small number of known resistance-conferring mutations,
such as those associated with ciproﬂoxacin resistance. In one study,
Stoesser et al. reported 95% concordance between phenotypic and
WGS-predicted susceptibility for seven commonly used agents
(amoxicillin, amoxicillin/clavulanic acid, ciproﬂoxacin, gentamicin,
ceftriaxone, ceftazidime and meropenem) by querying 143
assembled genomes from E. coli and K. pneumoniaewith a compiled
database of acquired AMR sequences and mutations in the
quinolone-resistance-determining regions of gyrA and parC [19]. An
even higher level of concordance (99.74%) between phenotypic
susceptibility testing and the WGS-predicted resistance to ﬁve
agents or classes of agents (b-lactams, chloramphenicol, sulpho-
namides, tetracycline and trimethoprim) in E. coli genomes was
reported in an earlier study using the same approach with a data-
base of 1411 different AMR sequences, conﬁrmed using simple
blotting and PCR approaches to the expected genes [14,20]. A recent
study investigating 76 E. coli isolates from farm cattle also showed
good phenotypeegenotype correlation (97.8%), with themajority of
discordant results attributed to the prediction of streptomycin
resistance [21].
There are important limitations to identifying the mode of
transmission of these acquired genes in short-read sequences due
to exclusion of repeat regions during the ‘cleaning’ stages while
initial contigs are assembled. This typically results in inaccuracies
in annotation. These are particularly marked in highly recombinant
plasmids, which unfortunately carry most of the AMR genes that
are relevant to b-lactam and aminoglycoside resistance in the
Enterobacteriaceae. Nevertheless, using sequencing technologies
with longer reads (and greater cost), such as PacBio and MinION,
improved their detection [22e25]. These bioinformatics challenges
also include the development of tools that can detect signature
sequences of AMR determinants (e.g. b-lactamase motifs) to iden-
tify potentially new variants conferring acquired AMR, which can
be explored in more detail.
Problems found or anticipateddgaps in the knowledge base
Chromosomal mutations that alter the cell membrane perme-
ability due to modiﬁcation in the structure or the levels of
expression of outer membrane proteins, antimicrobial efﬂux due to
efﬂux pumps such as resistance-nodulation-division and major
facilitator superfamily pumps, or changes in the lipopolysaccharide
structure have been linked to decreased susceptibility and resis-
tance to b-lactams, quinolones, chloramphenicol, tetracyclines,
tigecycline and colistin in Enterobacteriaceae, but have yet to be
fully elucidated. This makes comprehensive phenotypicegenotypic
comparisons difﬁcult [26e32] by limiting the sensitivity of the
WGS-based data. In particular, the relationships between chro-
mosomal mutations and the related phenotypic changes respon-
sible for resistance are not always well characterized and screening
genome sequences for insertion sequences interrupting or modi-
fying the expression of resistance-associated genes, including
intrinsic b-lactamases, could be problematic due to constraints
inherent in using short reads. Therefore, and in contrast to hori-
zontally acquired resistance genes, the ability of WGS to predict
resistance due to, or modulated by, chromosomal alterations is
likely to be restricted by existing knowledge, as in the case of car-
bapenem non-susceptibility resulting from the combination of
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antimicrobial agents for which the underlying genetic backgrounds
of resistance are yet to be fully characterized (e.g. amoxicillin-
clavulanic acid, nitrofurantoin, temocillin, colistin and tigecy-
cline). Screening for the loss-of-function mutations via nonsense
mutations, frameshifts or insertion elements that are meaningfully
less complex than substitutions affecting the structure, dynamics
and substrate speciﬁcity of resistance-conferring proteins is real-
istically achievable [33e35]. The effect of amino acid changes in
the transmembrane b-strand loop 3 that constitutes the porin
channel eyelet that was associated with diminished carbapenem
uptake in the endemic K. pneumoniae carbapenemase-producing
K. pneumoniae ST258 clone illustrates the complexity of interpret-
ing amino acid substitutions identiﬁed by WGS in the absence of
experimental evidence [36,37]. Recent studies have shown that the
genetic basis of resistance to colistin in K. pneumoniae clinical iso-
lates can be attributed in the majority of cases to alterations in the
mgrB regulator or the two component systems pmrAB or phoEQ that
regulate the expression of the biosynthesis pathway of lipid A
[29,38]. However, incorrectly inferring susceptibility remains the
risk if resistance is mediated by genuinely novel, undiscovered
genetic factors, as evidenced by the description of mcr-1, the ﬁrst
known transferable colistin resistance determinant [18].
The gaps in the existing knowledge of genotypeephenotype
relationships could be augmented in some cases by directly
detecting the levels of gene expression by sequencing RNA extracts.
This approach was successfully used as a proof-of-concept for the
detection of ompF down-regulation associated with cephalosporin
resistance and over-expression of the resistance-nodulation-
division pump component acrB leading to decreased susceptibil-
ity to quinolones, tetracycline and chloramphenicol in an E. coli
laboratory-selected mutant [39]. Although a similar approach
should also be feasible for the detection of hyper-production of
intrinsic chromosomal b-lactamases (e.g. AmpC in Enterobacter
spp.) the use of such methods, for which accuracy is highly
dependent on bacterial growth conditions, is likely to be conﬁned
to a sub-set of laboratories in the foreseeable future and will not be
considered further for the purposes of this document, which seeks
to examine widely used techniques only.
Summary
The relatively limited number of acquired resistance genes and
resistance-associated mutations that dominate epidemiologically
in the Enterobacteriaceae (comparedwith the large number of those
that have been reported in the resistome) could explain the high
levels of accuracy of genotypeephenotype correlation in published
studies andmeans that well-informed screening approaches can be
very accurate. However, susceptibility to some antimicrobial agents
will be harder to predict than for others and understanding the full
range of mechanisms and their interplay will require more study if
improved levels of accuracy across large, genetically diverse data
sets are to be achieved.
Salmonella spp.
Background
Molecular mechanisms conferring reduced susceptibility to
antimicrobial agents are relatively well characterized in Salmonella
spp. The majority of these are encoded by horizontally transferable
genes, which potentially makes genotypic detection a reliable
alternative to phenotypic testing as these genes generally assemble
into full-length genes when using short-read sequencing data, as
long as the quality and quantity of these are adequate to produce
good assemblies. In addition to acquired gene-based AMR, muta-
tionally acquired AMR also exists in Salmonella spp. The clinicallymost important examples currently are single or double mutations
in the gyrA DNA gyrase and parC topoisomerase genes leading to
reduced susceptibility to quinolones and ﬂuoroquinolones. Resis-
tance to third-generation cephalosporins due to acquired
extended-spectrum and AmpC b-lactamases is also clinically
important to consider.
Published studies
Very few comprehensive studies have been published where
phenotypic susceptibility data have been compared with the un-
derlying molecular mechanisms identiﬁed in WGS data sets from a
collection of Salmonella isolates. Zankari et al. used a set of 50
Salmonella enterica serovar Typhimurium isolates originating from
pigs and previously tested phenotypically against 17 different
antimicrobial agents as part of the DANMAP surveillance program
[20,40]. WGS was performed on these 50 isolates, of which 49
produced sufﬁcient WGS data to create draft genomes for analysis
with the RESFINDER web-tool. Here, complete agreement (100%
sensitivity and speciﬁcity) between tested and predicted suscepti-
bility/resistance phenotypes (S/R) was observed [20]. However, this
perfect correlation between phenotypes and genotypes generated
by RESFINDER was to some extent biased by (a) the fact that none of
the isolates showed phenotypic resistance to quinolones or ﬂuo-
roquinolonesdwhich would, in most cases, have been unnoticed
by RESFINDER as it currently does not detect chromosomally acquired
mutations leading to AMR; and (b) there was a relatively low level
of diversity among the resistance phenotypes and hence resistance
genes found.
In addition, a few studies exist where only a small number of
isolates have been analysed using both phenotypic and genotypic
methods. In a study of extremely drug-resistant Salmonella enterica
serovar Senftenberg, two isolates from Zambia were analysed both
by conventional phenotypic methods and by WGS analysis [41].
Here, genes conferring reduced susceptibility to nine drug classes
including ﬂuoroquinolones and extended-spectrum cephalospo-
rins, were identiﬁed, again with the use of the RESFINDER web-tool.
These isolates also demonstrated high-level resistance to ﬂuo-
roquinolones caused by mutations in GyrA (S83Y and D87G) and
ParC (S80I), which were identiﬁed manually. An underlying mo-
lecular mechanism was identiﬁed for all the AMR phenotypes dis-
played by the two isolates. In a similar study, two ESBL-producing
Salmonella enterica serovar Typhi isolates were tested phenotypi-
cally against 25 different antimicrobial agents belonging to ten
different classes [42]. Here, RESFINDER found seven different AMR
genes, which in combination could explain the observed AMR
phenotypes of the two isolates.
Problems found or anticipateddgaps in the knowledge base
The overall degree of resistance within Salmonella spp. varies
depending on the serovar and phage type; some may be associated
with resistance to particular antimicrobial agents, whereas others
may have an increased propensity for multidrug resistance. Di-
versity within the isolate panel tested will therefore be likely to
impact on the conclusions drawn regarding the utility of WGS for
AMR prediction in Salmonella spp.WGS should therefore be applied
to further isolate panels reﬂecting the diversity of Salmonella
serovars (and their common resistance phenotypes) associated
with clinical and veterinary infections. Included in these panels
should be representatives of some of the particularly multiresistant
clones that are currently circulating in human and animal pop-
ulations, e.g. serovars Kentucky, Infantis and monophasic Typhi-
murium. Nevertheless, recent data from the European Centre for
Disease Prevention and Control indicate that nearly 55% of Salmo-
nella spp. from humans are susceptible to all antimicrobial classes
tested, suggesting that resistance prediction in Salmonella spp. may
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resistance is the norm [43].
As with the other Enterobacteriaceae, detection of chromosomal
mutations leading to acquired antimicrobial resistance is a chal-
lenge that still needs to be addressed to be able to predict resistance
phenotypes fully based onWGS data. Priority should be afforded to
the detection of mutations leading to ﬂuoroquinolone resistance, as
this drug class has high clinical relevance and phenotypic resis-
tance is commonly detected in salmonellae. Development of ﬂuo-
roquinolone resistance can be a multifactorial process involving
acquisition of mutations leading to amino acid substitutions within
the topoisomerase genes and altered expression of outer mem-
brane proteins and/or multidrug efﬂux pumps. Fortunately, the
most common chromosomal mutations leading to acquired ﬂuo-
roquinolone resistance in salmonellae are well characterized; de-
cision rules to translate mutations into a predicted phenotype are
therefore available and can, in principle, be incorporated into
existing tools such as RESFINDER. This, however, requires detection of
amino acid variation rather than nucleotide variation, which is
currently used to detect (transferable) resistance genes. Other
possible candidates for detection of chromosomal mutations are
pmrA and pmrB, leading to reduced susceptibility to colistin [44].
Summary
The relatively limited studies that are available on the feasibility
of using WGS data to predict antimicrobial resistance in salmo-
nellae are showing promising results, but the impact of the sample
sets tested on genetic diversity needs to be explored in detail before
further conclusions are drawn about the use of WGS data for AMR
prediction in Salmonella spp.
Staphylococcus aureus
Background
Staphylococcus aureus exhibits intrinsic susceptibility to
commonly used antimicrobial agents. Resistance is associated with
mutations in core genes or the acquisition of speciﬁc antimicrobial
resistance genes. Generally, the history of antimicrobial resistance
in this species is associated with the evolution of resistance shortly
after the ﬁrst introductions of a new agent into clinical practice, for
example resistance tomethicillinwas detected in clinical isolates of
S. aureus within a year of introduction into the UK [45]. The prob-
lem of resistance in this species has driven extensive studies to
identify the genetic basis of resistance, and as such there is a large
body of literature documenting resistance mechanisms for most of
the clinically relevant agents used. This has revealed a well-
characterized spectrum of mechanisms bestowing resistance in
S. aureus, and in the cases of some AMR determinants, in other
staphylococcal species and also in other genera. This has proved to
be a valuable resource for the in silico prediction of antimicrobial
resistance and has contributed to the overall value of the results.
Published studies
To date, several studies have been published that demonstrate
the ability to predict antimicrobial resistance from genome
sequence data [46e50]. Initial studies examined the concordance
between phenotype and genotype [46e48], and more latterly
blinded studies have made predictions [49]. In addition, bioinfor-
matics resources have been produced that will generate predictions
of antimicrobial resistance from genome sequence data [51].
The initial demonstration of the potential of WGS data to predict
AMR as a clinical tool came from proof-of-concept studies using the
benchtop Illumina MiSeq platform to investigate suspected
methicillin-resistant S. aureus (MRSA) outbreaks. K€oser et al.
sequenced 14 isolates belonging to four different clonal complexesof S. aureus, and demonstrated 100% concordance of the in silico
resistance prediction with the phenotypic results for 13 different
agents (cefoxitin, erythromycin, ciproﬂoxacin, gentamicin, tetra-
cycline, rifampicin, fusidic acid, mupirocin, clindamycin, kana-
mycin, tobramycin, trimethoprim and linezolid) [46]. The authors
used an in-house database of resistance determinants derived from
literature mining and mapped sequence reads to a resistome
pseudo-molecule (concatenated resistance genes in a single DNA
sequence), followed by manual inspection to predict the resistance
proﬁle of each isolate. Investigating an MRSA cluster in an intensive
care unit, Eyre et al. sequenced ten isolates belonging to the same
spa-type (t5973) and conducted in silico predictions for penicillin
and tetracycline [47]. The authors took a different bioinformatics
path to investigate the antimicrobial resistance, using the de novo
assemblies to look for the presence and absence of two genes, tetK
and blaZ. In all cases the presence of these genes correlated with the
phenotypic resistances to respective agents.
Examining 13 isolates belonging to USA300 clone, Lee et al.
predicted the antimicrobial resistance proﬁles for nine agents
(ciproﬂoxacin, clindamycin, doxycycline, erythromycin, genta-
micin, oxacillin, tetracycline, trimethoprim-sulfamethoxazole and
vancomycin) in complete concordance with the phenotypic results
[50]. The authors generated in silico predictions from short-read
data using SRST2, a mapping-based tool for fast and accurate
detection of genes and alleles from WGS data from a user-deﬁned
database [52]. In the case of this study, details of the antimicro-
bial resistance database used were not provided.
The effectiveness of in silico prediction for antimicrobial resis-
tance in S. aureus has been further demonstrated in larger studies,
both in terms of the number of isolates and also the agents inves-
tigated. Using the genome data of 193 isolates belonging to a global
collection of ST22, Holden et al. applied a mapping based approach,
coupled with manual inspection, to identify molecular de-
terminants that explained 99.8% of the measured phenotypic
resistance traits [48]. In total, 847 resistance traits were tested for
18 agents (penicillin, oxacillin gentamicin, linezolid, erythromycin,
clindamycin, ciproﬂoxacin, fusidic acid, mupirocin, moxiﬂoxacin,
trimethoprim-sulfamethoxazole, tetracycline, vancomycin, teico-
planin, rifampicin, fosfomycin, tigecycline and daptomycin), using
an enhanced version of the library used by K€oser et al. [46] in their
earlier study.
Using the WGS data and phenotype data for 501 S. aureus iso-
lates as a derivation set to optimize predictions for 12 agents
(penicillin, methicillin, erythromycin, clindamycin, tetracycline,
ciproﬂoxacin, vancomycin, trimethoprim, gentamicin, fusidic acid,
rifampicin and mupirocin), Gordon et al. then conducted a blind
validation of their reﬁnedmethod on a query set of 491 isolates and
demonstrated sensitivity of 0.97 and speciﬁcity of 0.99 [49]. As with
their previous study, the authors used de novo assemblies and
BLASTn for their in silico prediction [47]. In their resistance data-
base 18 acquired genes were included: blaZ, mecA, msr(A), erm(A),
erm(B), erm(C), erm(T), tet(K), tet(L), tet(M), vanA, fusB, far, dfrA,
dfrG, aacA-aphD, mupA and mupB, and variation in six core genes:
gyrA (n ¼ 6), grlA (n ¼ 13), grlB (n¼ 6), fusA (n ¼ 59), rpoB (n ¼ 28)
and dfrB (n ¼ 8).
In a signiﬁcant departure from previous studies in S. aureus,
Bradley et al. described a stand-alone tool, MYKROBE PREDICTOR (http://
www.mykrobe.com/), for antimicrobial resistance prediction
directly from FASTQ ﬁles and which does not rely on mapping or
assembly-based approaches [51]. This tool uses a de Bruijn graph-
based approach to compare sequence reads to a reference graph
representation. The method has the advantage of being faster than
the mapping and assembly-based methods, and it can also identify
minority variants in sequencing data and therefore identify po-
tential contamination issues. In their study, Bradley et al. used 495
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collection of WGS data from a further 471 isolates. The tool uses the
Gordon et al. database [49] with some additional reﬁnements and
makes predictions for the same 12 agents. Using the tool, Bradley
et al.were able to demonstrate sensitivity of 99.1% and speciﬁcity of
99.6% for the genotypic predictions in comparison with the
phenotypes.
Problems found or anticipateddgaps in the knowledge base
Genetic instability. The evolution of antimicrobial resistance in
S. aureus occurs by point mutation in core genes, and also by hor-
izontal acquisition of resistance genes via mobile genetic elements.
In the studies conducted so far, it is apparent that in some cases the
relative genetic instability of mobile genetic elements carrying
resistance genes can be a cause of discrepancy in the genotypic and
phenotypic comparisons. One of the agents most prone to this
problem is erythromycin. In S. aureus, genes encoding erythro-
mycin resistance are often found on plasmids, such as in the case of
erm(C). The instability of the erm(C)-carrying plasmid has beenwell
documented, and it can be lost during passage of isolates in the
laboratory. In the study by Holden et al. [48] discrepancies in
erythromycin resistance prediction were thought to be due to the
loss of the erm(C) during propagation and transfer between testing
and genomics laboratories. Similar observations about the loss of
the SCCmec element from the chromosome have also been made,
which can account for discrepancies in cefoxitin resistance, albeit at
a far lower frequency. In this case, evidence of the deletion of the
whole SCCmec element carrying the mecA gene encoding cefoxitin
resistance can be observed. Genetic stability of core components
can also affect the observed resistance levels for some agents in
S. aureus. Hetero-resistance has been observed whereby a sub-
population of cells in a cultured population exhibits a higher MIC
than their ‘siblings’. WGS of sub-populations has uncovered genetic
variation associated with hetero-resistance to vancomycin, dapto-
mycin and oxacillin [53,54].
Gaps in the knowledge base. Although the studies that have been
published so far have generally demonstrated the effectiveness of
in silico resistance prediction, there is evidence emerging that the
performance for some agents will be less accurate than for others.
Aanensen et al. [55] recently conducted a blinded study of 308
isolates and phenotypically tested a range of agents (16 agents were
tested against all isolates: penicillin, cefoxitin, ciproﬂoxacin, mox-
iﬂoxacin, amikacin, gentamicin, tobramycin, erythromycin, clinda-
mycin, tetracycline, tigecycline, fusidic acid, linezolid, mupirocin,
rifampicin, trimethoprim; and for MRSA isolates teicoplanin, van-
comycin and daptomycin were also tested). Overall, the total per-
formance of the in silico prediction was in line with previous
studies, with 98.6% concordance, although for some agents, such as
amikacin (92.5% concordance) and teicoplanin (97.5% concor-
dance), the in silico prediction proved less effective.
For some agents there are clearly gaps in the knowledge base for
the genetic basis of resistance that require further investigation. For
example, in the case of glycopeptides, such as vancomycin, the
multiplicity and diversity of mutational changes that are suspected
to be linked with increased MICs in S. aureus is so great that they
confound an accurate prediction of susceptibility or resistance
[56e58].
Laboratory variation. Discrepancies between the genotype and
phenotype in some studies have been revealed to be laboratory
artefacts and errors, where phenotypic re-testing led to concor-
dance. Technical variation in some of the tests is also a possible
contributing factor in mis-matches. For example, in the study by
Aanensen et al. [55] it was noted that in the case of ﬁve isolates thathad incorrect in silico predictions for mupirocin. The inhibition
zone of these isolates (all at 29mm)were so close to the ECOFF (WT
30mm), that it cannot be ruled out that technical variations in the
phenotypic AST might have inﬂuenced results or that it signals that
a revision of the zone diameter ECOFF for mupirocin is needed.
Summary
The in silico prediction of AMR susceptibility for S. aureus is
effective for most clinically relevant agents. There are, however,
some agents for which it is more challenging to make predictions
and further investigation is required to characterize the genetic and
phenotypic basis of resistance.
Streptococcus pneumoniae
Background
Streptococcus pneumoniae is clinically a highly important com-
munity pathogen, in which genetic detection of acquired resistance
is particularly challenging because most resistance results from
development of mosaic genes or mutations in chromosomally
encoded genes [59]. The most clinically important groups of anti-
microbial agents with activity against pneumococci are the b-lac-
tams, macrolides, tetracyclines and newer ﬂuoroquinolones (e.g.
moxiﬂoxacin). WGS-based approaches have been used for charac-
terizing resistance mechanisms for several of these antimicrobial
groups. However, no speciﬁc, user-friendly database has been
developed so far, and WGS has mostly been used to study new
mechanisms, and not in the context of predicting phenotypic
resistance from whole genome data.
Published studies
For b-lactams, resistance is mostly mediated through the
development of mosaic genes encoding altered penicillin-binding
proteins (PBPs), as a result of intraspecies and interspecies DNA
transfer by natural transformation [60]. Variants of PBP2x, PBP2b
and PBP1a are considered most relevant to penicillin resistance in
pneumococci. However, there have also been reports of non-PBP-
mediated resistance, such as enrichment in branched-chain mur-
opeptides and mutations in genes encoding other enzymes
involved in the peptidoglycan synthesis [61]. Fani et al. usedWGS to
study mutants selected for penicillin resistance by stepwise peni-
cillin increments until reaching a ﬁnal MIC of 2 mg/L [61].
Sequencing was done by the 454 platform, generating a genome
assembly of 28 coverage, with 97% of the reads assembled into 78
large contigs. Comparative sequence analysis identiﬁed mutations
that were conﬁrmed by Sanger sequencing. PBP2x mutations were
shown to be important, but the relationship between genotypic and
phenotypic resistance was complex, with a mutated iron transport
system found in several of the resistant mutants.
Later work by the same research group proposed phenotypic
reconstruction by whole genome transformation of penicillin-
susceptible S. pneumoniae of known genetic backgrounds with
genomic DNA from resistant clinical isolates [62]. This procedure
would then be followed by WGS of the antimicrobial-resistant
transformants. Selection of transformants was done by gradually
increasing increments of penicillin concentrations. The genome
sequences of the fully resistant and intermediate-step trans-
formants were compared with the reference genome of the wild-
type S. pneumoniae strains used in the experiments. The study
conﬁrmed the importance of mosaic PBP2x, PBP2b and PBP1a, but
also suggested a role for PBP2a in some isolates. In another study,
analysis of cefotaxime-resistant mutants revealed mosaic PBPs as
well as mutations in other genes important for peptidoglycan
synthesis [63]. Although these data suggest that predicting
phenotypic b-lactam resistance based on WGS could be feasible in
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conﬁrm this.
Macrolides also have clinically important activity against S.
pneumoniae. Resistance is often mediated through RNA methylase
(erm) or macrolide efﬂux (mef) genes, both of which are coupled to
mobile genetic elements. One study was conducted in the USAwith
147 pneumococcal isolates collected over an 18-year period both
before and after the introduction of conjugate vaccines [64]. Ge-
nomes were then compared and mapping of macrolide resistance
genes and their genetic environment was carried out. Resistance
genes were detected in all isolates, but the study was in no way
investigator-blinded, as all included isolates were macrolide-
resistant by phenotypic methods.
Lupien et al. investigated mutants selected for resistance to
tetracyclines [65]. Resistance to tetracycline in bacteria occurs
through enzymatic inactivation or, more often, by active efﬂux (via
intrinsic or acquired pumps) or by ribosome protection. Resistance
to tetracyclines in pneumococci is very common, and most often
mediated by tet genes, which are found on mobile genetic ele-
ments. Lupien et al. usedWGS to investigate not only genomic DNA,
but also RNA sequencing libraries depleted of rRNA. RNA expression
was compared in parent strains and mutants, identifying differen-
tially expressed genes. Quantitative RT-PCR was used to conﬁrm
over-expression of some of the genes identiﬁed by comparison of
sequenced mRNA in mutants and wild-type strains. Gene ontology
classiﬁcation of genes whose expression is signiﬁcantly altered in S.
pneumoniae therefore seems to be a feasible way of studying new
chromosomal resistance mechanisms, although this approach has
not been used on clinical isolates. Finally, whole genomic DNA
transformation combined with WGS has also been used to study
isolates with resistance to ciproﬂoxacin [66]. In addition to iden-
tifying efﬂux (using quantitative RT-PCR) and quinolone-
resistance-determining region mutations, the methodology could
also point to the potential role of mutations in drug transporters
and redox enzymes in ciproﬂoxacin resistance.
Summary
A number of mechanistic studies, including whole genome
transformation, have been carried out with laboratory mutants.
These studies have shed light on a number of putative new
mechanisms, but there is at present a lack of studies of the utility of
WGS for predicting phenotypic resistance to agents used in the
treatment of S. pneumoniae.
Neisseria gonorrhoeae
Background
Gonorrhoea is a global public health concern with the World
Health Organization estimating 106 million cases every year [67].
Neisseria gonorrhoeae has developed resistance to every class of
antimicrobial used to treat infections caused by the organism [68].
The emergence of multidrug-resistant N. gonorrhoeae has led the
US CDC to classify it at an urgent threat level requiring serious
public health attention [69]. Empiric combination therapy with
intramuscular ceftriaxone and oral azithromycin is recommended
for ﬁrst-line treatment in North America and Europe [70,71].
Hence, this report focuses on the mechanisms of resistance to these
antibiotics and the use of WGS to predict cephalosporin and azi-
thromycin resistance.
The CLSI has set the clinical breakpoint for susceptible isolates
for both ceftriaxone and ceﬁxime at 0.25 mg/L, although no
breakpoint for resistance has been established [72]. EUCAST
established a clinical resistance breakpoint for ceftriaxone and
ceﬁxime at >0.125 mg/L [73]. However, treatment failures with
cephalosporin monotherapy have recently been observed in anumber of countries in cases where the ceﬁxime MICs for the
infecting gonococci were as low as 0.032 mg/L [74e78]. Although
there are no azithromycin breakpoints established by CLSI, sus-
ceptible and resistant breakpoints have been set by EUCAST at
0.25 mg/L and >0.5 mg/L, respectively [73]. In addition, the CDC
has used a resistance breakpoint for azithromycin at 2 mg/L [79].
Numerous genetic mechanisms exist in N. gonorrhoeae for the
development of elevated MICs to the extended-spectrum cepha-
losporins (ceftriaxone and ceﬁxime). Alterations in penA, which
encodes PBP2, have been described either through amino acid al-
terations (A501, G542, P551) or through the acquisition of a penA
mosaic allele, which contains segments of penA from non-
gonococcal Neisseria species [80e82]. These alterations confer
reduced susceptibility to extended-spectrum cephalosporins
mediated by reduced binding to PBP2 [83]. Upregulation of the
MtrCDE efﬂux pump via a deletion in the promoter at e35 (A-del)
or alterations of the MtrR repressor protein at positions G45D and
A39T have also been associated with decreased susceptibility to the
extended-spectrum cephalosporins [80,84]. A third mechanism for
increased MICs to extended-spectrum cephalosporins involves al-
terations in the PorB1b porin at amino acid positions G120 and
A121. These permeability changes may reduce entry of extended-
spectrum cephalosporins into the cell leading to reduced suscep-
tibility [80,84].
Published studies
Only a few published studies have used WGS to examine the
phenotypic and genotypic antimicrobial resistance patterns
observed in N. gonorrhoeae. The ﬁrst such study examined the
genomes of 236 isolates of N. gonorrhoeae collected in the USA
from 2009 to 2010, and included 118 isolates with decreased
susceptibility to ceﬁxime (MIC 0.25 mg/L) [85]. The mosaic penA
XXXIV allele was present in 115 of 118 isolates with decreased
ceﬁxime susceptibility and one other isolate carried a novel
mosaic allele termed XLI [86]. No other alleles were clearly asso-
ciated with reduced susceptibility to ceﬁxime. A second study
examined the genomes of 76 N. gonorrhoeae from numerous
countries [87]. The mosaic penA XXXIV allele once again had the
best positive predictive value, with this locus detected in six of
seven ceﬁxime-resistant isolates. Mutations in the mtrR/mtrCDE
operon promoter region and penB gene did not have such a strong
predictive value, being found in only two of seven and three of
seven ceﬁxime-resistant isolates, respectively. A third study
applied WGS to 169 Canadian isolates of N. gonorrhoeae with
various antimicrobial resistance patterns [88]. There were 67
isolates with ceftriaxone MICs ranging from 0.125 to 2 mg/L. Of
these, 40 (59.7%) harboured the penA mosaic, and all but one
isolate had either porBmutations or themtrR promoter mutations.
Of the remaining 27 isolates without the penAmosaic, all had porB
mutations and only a single isolate did not contain a mutation in
the mtrR promoter. However, when isolates with low MICs of
ceftriaxone (<0.032 mg/L; n ¼ 65) were examined, one isolate
(1.5%) was found to have the penA mosaic, 33 (50.7%) isolates
contained mtrR promoter mutations, and ﬁve isolates also con-
tained mutations in porB.
A second highly clinically signiﬁcant phenotype that has been
examined forN. gonorrhoeae is azithromycin resistance. The rates of
azithromycin resistance in N. gonorrhoeae have been increasing in
recent years in many countries, and the emergence of high-level
resistance (MIC 256 mg/L) has been reported from the UK,
Argentina, Canada and the USA [89e93]. The genetic mechanisms
of resistance to azithromycin in N. gonorrhoeae include: accumu-
lated changes in the four different alleles of the 23S rRNA genes; the
presence of a 23S rRNA methylase encoded by erm(A), erm(B),
erm(C) or erm(F); mutations in rplD and rplV; as well as the penB
M.J. Ellington et al. / Clinical Microbiology and Infection 23 (2017) 2e2212andmtr operon genes described above for cephalosporin resistance
[94e96].
Although reports describing WGS-based detection of these
mechanisms are limited, there have been attempts to compare the
azithromycin resistance phenotype with the WGS genotype and
these are discussed below.
Problems found or anticipateddgaps in the knowledge base
Ezewudo et al. examined two isolates that were resistant to
azithromycin and found that one isolate contained the 23S rRNA
mutation whereas the other did not contain any of the known
mutations examined [87]. In a second study, involving the WGS
analysis of 213 Canadian azithromycin-resistant isolates, 23S rRNA
mutations A2045G and/or C2597T, disruptions in the mtrR pro-
moter, or the presence of erm(C) were strongly associated with
phenotypic resistance [88]. Seventy N. gonorrhoeae contained only
the mtrR e35 deletion, and of these 21 were susceptible to azi-
thromycin, suggesting that other potential but unknown mecha-
nisms conferring resistance may exist.
Although there is strong association with penA mosaic alleles
and reduced susceptibility to extended-spectrum cephalosporins,
caution is required with this data set as it relates to predicting the
extended-spectrum cephalosporin MIC phenotype. The study by
Demczuk et al. suggested that reduced susceptibility to ceftriaxone
remains complex, involving additional genetic markers [88]. In
addition, there has been a report of the mosaic penA allele XXXVIII
displaying a susceptible phenotype to extended-spectrum cepha-
losporins [97].
Summary
Inferring resistance to extended-spectrum cephalosporins and
azithromycin in N. gonorrhoeae is possible with a high probability if
certain genetic markers are detected in WGS data. However, the
elevated MICs for some isolates result from combinations of mul-
tiple genetic changes, and further mechanisms of resistance have
yet to be elucidated. Hence, predicting resistance to these antimi-
crobial agents can be problematic. Additional studies are required
before the use ofWGS can be advocated for use on a routine basis to
predict resistance for these antimicrobial agents.
Mycobacterium tuberculosis complex
Background
Tuberculosis (TB) is caused by members of the Mycobacterium
tuberculosis complex (MTBC) and, more rarely, by Mycobacterium
canettii [98]. MTBC is monomorphic and strictly clonal and anti-
microbial resistance is therefore only caused by chromosomal
changes. These are single nucleotide polymorphisms (SNPs) in the
vast majority of cases, but small in-frame insertions/deletions
(indels) in essential resistance genes and large indels in non-
essential genes are also possible [99,100]. By contrast, M. canettii
is genetically diverse and displays evidence of recombination and
lateral gene transfer [98]. The resistancemechanisms in this species
are unclear [101e103].
Phenotypic susceptibility testing for TB is expensive, technically
challenging and time-consuming owing to the slow growth rate of
MTBC [104]. Current molecular AST assays only interrogate the
most frequent mutations conferring resistance to a limited number
of drugs. In theory, this limitation can be overcome by WGS. In
practice, however, routine WGS of all isolates from TB cases is un-
likely to be cost-effective if performed to predict antimicrobial
susceptibility alone, despite the decreasing cost of WGS [105,106].
This is primarily because rates of drug resistance are low (typically
<5%) in countries that can afford WGS [107]. Instead, the main
driver for the introduction of WGS for all TB cases will be the desireto replace traditional typing techniques by the ultimate resolution
provided by WGS to improve outbreak investigations [108e110].
Moreover, WGS from the initial liquid culture can replace current
techniques for pathogen identiﬁcation (WGS directly from a clinical
sample is technically possible, but less reliable and prohibitively
expensive for clinical practice at the moment [111,112]). In this
scenario, the sequence data can also be used to rule in resistance at
no additional cost [106].
Published studies
Several large-scale studies reportingWGS of MTBC have focused
on elucidating the genetic basis of antimicrobial resistance, which
complement more focused efforts [106,113e122]. Nevertheless,
major gaps in this area remain, as discussed below. Several tools
have been developed to automate WGS data analysis, although
most do not meet clinical standards because they do not provide
the necessary record keeping capabilities, have not been evaluated
extensively, and often there are no plans to accredit them
[51,106,123e127]. One exception is the analysis infrastructure that
is currently being evaluated by Public Health England for clinical
accreditation and routine use of WGS for TB in the UK [106].
Problems found/anticipateddgaps in the knowledge base
As discussed brieﬂy in the section above on ‘Categories of sys-
tematic errors in WGS predictions of AMR’, three main challenges
limit the utility of genotypic AST compared with phenotypic
alternatives.
(a) Systematic errors due to inadequate limit of detection of WGS.
AST for TB is usually done on a signiﬁcant fraction of the
primary culture, as opposed to just one to three colonies
from a primary agar plate, which is the approach taken for
the vast majority of other clinically relevant bacterial path-
ogens. Resistance is deemed clinically signiﬁcant if resistant
organisms are present at or above a critical proportion,
which is set at 10% for pyrazinamide and at 1% for the
remaining antimicrobial agents, and reference standard
phenotypic AST (i.e. the proportion method) is calibrated to
detect resistance at this limit [128,129]. The limit of detection
of traditional genotypic AST methods is poorer and depends
on the assay and speciﬁc mutation, which can result in sys-
tematic false-negative results for strains with low-level
hetero-resistance [130e132]. The magnitude of this source
of error depends on several factors, including the frequency
of mixed infections with unrelated strains that have different
susceptibilities and the proportion of resistance that is
transmitted versus resistance that evolves during treatment
[133]. In practice, these factors vary between patient groups,
geographic settings and antimicrobial agents. Moreover, the
precise mechanism of resistance is relevant in this context.
Low-level hetero-resistance SNPs can be identiﬁed by
increasing the sequencing coverage, although this makes
WGS prohibitively expensive in a clinical context at the
moment [106,134]. This strategy is not an option for hetero-
resistance indels, particularly large ones, because of the
limited read lengths of the most commonly used platforms
for clinical sequencing, coupled with the fact that most
analysis algorithms are not optimized to identify indels [135].
(b) Systematic errors due to poorly deﬁned breakpoints for
phenotypic AST used as the reference standard for the validation
of WGS-based AST. The clinical breakpoints, known as critical
concentrations (CCs) in the TB ﬁeld, are currently deﬁned by
the CLSI and the WHO [136,137]. Clinical breakpoints should
be deﬁned by committees based on representative MIC dis-
tributions, pharmacokineticepharmacodynamic data and,
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are difﬁcult to obtain for TB agents [10,138]. In practice,
however, the evidence used to set the current CCs is not clear
and emerging data from systematic MIC testing and phar-
macokineticepharmacodynamic studies indicate that the
CCs for some agents need to be revised [137e142]. In addi-
tion, no CCs exist for some second-line drugs, such as clofa-
zimine [137]. Finally, the reproducibility of some phenotypic
ASTmethods is poor, particularly for second-line drugs [137].
A new EUCAST Subcommittee has been launched to set
breakpoints for TB using the same rigorous and transparent
methodologies used for other pathogens [10,143].
(c) Incomplete understanding of the genotypic basis of phenotypic
resistance. The Bill & Melinda Gates Foundation has funded
the Foundation for Innovative New Diagnostics and the
Critical Path to TB Drug Regimens to create a clinical grade
database, akin to the HIV Stanford resistance database, to
enable the interpretation of TB WGS data for AST [144]. As
part of this effort, the Foundation for Innovative New Di-
agnostics (FIND) and the Critical Path to TB Drug Regimens
will, together with the World Health Organization, New
Diagnostic Working Group of the Stop TB Partnership, the
USA CDC and the National Institute of Allergy and Infectious
Diseases, collect and analyse WGS with associated pheno-
typic AST results for tens of thousands of isolates to gain
sufﬁcient conﬁdence in the association between particular
mutations and resistance, as even the largest WGS studies
published to date have been underpowered and were not
designed to achieve this goal [118,122].
The complexity of this task depends onwhether a resistance gene
is essential or non-essential. In the former case, only a limited
spectrum of resistance mutations is possible. Consequently, the
correlation between genotype and phenotype should be relatively
easy to resolve, provided that methodological problems such as
poorly deﬁned CCs are addressed (e.g. there is a near perfect corre-
lation between genotype and phenotype for rifampicin resistance
and rpoBmutations, although this can depend on the medium used
for phenotypic AST) [145e147]. The situation with non-essential
genes is more complicated. For genes that are non-essential
in vitro as well as in vivo, it is impossible to study the genetic basis
of resistance comprehensively given that there are toomany possible
resistance mutations. The best example of this type of resistance
gene is pncA, which is responsible for the activation of the pro-drug
pyrazinamide [148]. Any loss-of-function mutation in this gene can
confer resistance and awide variety of mutations are found clinically
(e.g. more than 4000 single codon changes are possible in pncA,
excluding start codon changes and nonsense mutations, not all of
which will cause resistance). By combining large data sets it is
possible to distinguish resistance mutations from neutral poly-
morphisms, but novel mutations will continue to be discovered,
albeit at a lower rate over time [122,149]. Similar considerations
apply to the catalase-peroxidase KatG, which is required for the
activation of the pro-drug isoniazid [150]. The gene encoding KatG
has been found to be non-essential in vitro, but clinically most
resistance-associated mutations within it are not selected, suggest-
ing that they may be counter-selected [151]. By contrast, the KatG
S315Tchange confers only a low ﬁtness cost [152]. Consequently, this
mutation accounts for the majority of isoniazid resistance clinically
[122]. The remaining isoniazid resistance is due to a large number of
rare mutations that are impossible to study in their entirety.
Summary
Some of the aforementioned challenges to introducing and
validating WGS for AST of TB can be overcome over time. Forexample, the ability of WGS to detect hetero-resistance will
improve as the cost of sequencing decreases and read lengths
improve. Similarly, the ongoing re-evaluation of CCs will probably
resolve some of the current systematic differences between geno-
type and phenotype. Moreover, the pooling of large data sets will
clarify the role of rare resistance mechanisms and the level of
resistance conferred by different resistance mutations or mecha-
nisms. For example, some low-level isoniazid-resistant strains due
to inhA mutations remain treatable with higher doses of the agent
and the same may apply for some strains with low-level resistance
to new-generation ﬂuoroquinolones (codon 90 mutations of gyrA)
[136,153,154]. However, it is impossible to study the genetic basis of
antimicrobial resistance to all clinically relevant agents compre-
hensively because of the large number of possible resistance mu-
tations for some agents. This means thatWGS canmainly be used to
rule in resistance, as opposed to rule out resistance. Nevertheless,
this constitutes a signiﬁcant improvement in current clinical
practice, asWGS directly from the ﬁrst positive culture would allow
for established resistance mutations to key agents to be identiﬁed
rapidly, thereby allowing treatment regimens to be adjusted within
days as opposed toweeks or evenmonths for phenotypic AST [155].
Based on these results, reference laboratories could also immedi-
ately commence phenotypic AST for all remaining relevant agents,
including second-line agents (which are usually only tested if
resistance to ﬁrst-line agents is found, which introduces long de-
lays). Consequently, WGS is unlikely to completely replace pheno-
typic AST for TB in the near future, but will result in less phenotypic
testing over time and in more rapid identiﬁcation of resistant iso-
lates inmany cases. However, it is likely that different countries will
adopt their own policies in terms of how much phenotypic
conﬁrmation of genotypic results is required, based on the re-
sources available and the local rates of resistance.
Clostridium difﬁcile
Background
Clostridium difﬁcile is the leading cause of healthcare-associated
diarrhoea, the severity of which may vary from mild and self-
limiting symptoms to fulminant disease, including pseudomem-
branous colitis. Hospital outbreaks are occurring with an increasing
frequency, and the most severe outbreaks have been caused by
hypervirulent C. difﬁcile strains 027/NAP1, although other ribotypes
(such as 078/NAP7&8) also seem to have the ability both to cause
outbreaks and severe disease in affected individuals.
Acquired phenotypic resistance to tetracyclines, clindamycin,
ﬂuoroquinolones and rifampicin and corresponding resistance
genes have frequently been reported in C. difﬁcile and moxiﬂoxacin
resistance is used as an epidemiological marker for hypervirulent
strains, and for ribotype 027 (NAP1) in particular. However, resis-
tance to the agents that are used as primary therapeutics for
C. difﬁcile infection (i.e. vancomycin, metronidazole and ﬁdax-
omicin) is less common.
Phenotypic AST of C. difﬁcile suffers from some drawbacks. As
anaerobic conditions are required, it is costly and time-consuming
and therefore often not routinely performed in the clinical labo-
ratory and the correlation between in vitro susceptibility and clin-
ical outcome in the individual patient has not been thoroughly
studied. In light of this, genotypic AST using WGS appears an
attractive alternative. Although resistance to ﬁdaxomicin has been
associated with mutations in genes encoding RNA polymerase
(rpoB and rpoC) or in the marR homologue CD22120, the mecha-
nisms underlying resistance to vancomycin and metronizadole are
less well deﬁned.
Some of the main lineages of C. difﬁcile contain a vanG locus,
which is expressed but does not appear to play a role in resistance
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been identiﬁed that are resistant to vancomycin. Two laboratory-
derived vancomycin-resistant isolates have been described. One
had a substitution mutation in the rpoC gene and the second had
two mutations, one in murG (CD2725) and the second in a locus
named CD3659 [157].
Nitroimidazole genes (nimAeE) associated with metronidazole
resistance in other anaerobic species, including several species of
the Clostridium genus, have not been described in C. difﬁcile. The
exact mechanism(s) behind reduced susceptibility to metronida-
zole in C. difﬁcile still remains to be determined, although there
have been several reports of strains exhibiting elevated MICs. Such
reports of metronidazole resistance have all observed loss of the
resistant phenotype after passaging or low temperature storage
[158e160]. There has been one reported clinical isolate, 027/NAP1
from Canada, that initially had an unstable resistance phenotype,
but after serial passage in the presence of metronidazole the
phenotype became stable [161]. WGS comparisons between the
resistant and reverted susceptible isolate revealed many SNPs be-
tween the two isolates [161]. Proteomic analysis of these isolates
suggested that amultifactorial responsemay be associatedwith the
high-level metronidazole resistance observed [162]. Hence, the
genetic mechanism for metronidazole resistance in C. difﬁcile re-
mains elusive.
Gaps in the knowledge base
To date there have not been any publications of large-scale
studies comparing phenotypic with WGS-based AST for C. difﬁcile.
Summary
AST of C. difﬁcile using WGS could be a useful tool, both for
guiding the choice of treatment of the individual patient and for
epidemiological purposes. However, the knowledge gaps regarding
the mechanisms underlying resistance to several of the ﬁrst-line
treatment options pose a great challenge. Studies comparing
WGS-based approaches with phenotypic testing are needed and
future work on resistance mechanisms to frontline antimicrobials
are required.
Acinetobacter baumannii and Pseudomonas aeruginosa
Background
Among non-fermentative Gram-negative bacteria Pseudomonas
aeruginosa and Acinetobacter baumannii are important pathogens
due to their ability to cause a variety of opportunistic infections,
persist in the hospital environment and acquire antimicrobial
resistance [163e165]. Genomic studies have shown that both
P. aeruginosa and A. baumannii are associated with high genomic
diversity and gene content due to frequent transfer/acquisition of
mobile genetic elements, mobilization of insertion sequence ele-
ments, insertion sequence-mediated deletions and genome-wide
homologous recombination [166e172]. In addition to being
intrinsically resistant to many antimicrobial agents [11], the in-
crease in multidrug-resistant and in particular carbapenem-
resistant P. aeruginosa and A. baumannii has resulted in infections
caused by extensively drug-resistant and even pan-drug resistant
isolates with very limited or no validated therapeutic options
[166,173e175]. High-risk clones of both species have been identi-
ﬁed as responsible for the spread of important resistance genes,
such as those encoding carbapenemases [175,176].
In both P. aeruginosa and A. baumannii acquired resistance genes
are associated with various horizontally acquired resistance ele-
ments, although the majority of acquired resistance genes exist as
gene cassettes in integron structures [175,177]. In A. baumannii these
resistance elements are frequently clustered in antimicrobialresistance islands, which vary in structure, size and genomic loca-
tion [167], and plasmid-borne resistance genes also contribute to
the evolution of antimicrobial resistance in both species [175,178]. In
addition, both species, and in particular P. aeruginosa, have an
extraordinary capacity for modiﬁcation of endogenous genes
affecting functions such as membrane permeability, efﬂux, expres-
sion of intrinsic b-lactamases, antimicrobial targets and regulatory
genes contributing to multidrug resistance [164,175,179].
Published studies
To date, few comprehensive studies have investigated the
concordance between phenotypic AST and WGS-based resistance
prediction for P. aeruginosa or A. baumannii. Kos et al. related
phenotypic susceptibility data for meropenem, levoﬂoxacin and
amikacin to the genome sequences of approximately 390 clinical
isolates of P. aeruginosa [180]. The sensitivity and speciﬁcity for
genotypic inference of meropenem and levoﬂoxacin resistance
were 91% and 94%, respectively. In contrast, a genotypic marker for
amikacin resistance was identiﬁed for only 60% of the amikacin
non-susceptible isolates. In addition, 30 of 283 amikacin-
susceptible isolates were found to harbour genes associated with
amikacin resistance. This is in contrast to a study by Wright et al.,
where a strong association between amikacin resistance and the
presence of aphA6 and armA genes was observed in a collection of
75 clinical isolates of A. baumannii [181].
Although there is a lack of phenotypicegenotypic comparison
studies with respect to prediction of clinical resistance, several
genomic studies have been performed for epidemiological pur-
poses and to decipher mechanisms of resistance to various agents
in selected resistant isolates [167,182,183]. These studies are
important to identify both intrinsic and acquired genotypic resis-
tance determinants associated with resistance to various agents.
For instance, recent investigation of isogenic colistin-susceptible
and colistin-resistant isolates of both P. aeruginosa and
A. baumannii from single patients revealed novel determinants
associated with colistin resistance [184,185]. Further, the use of
WGS as a tool to predict antimicrobial resistance has recently been
studied using 178 A. baumannii bacterial genomes to evaluate the
antimicrobial resistance gene database ARG-ANNOT and it was
shown that such an approach could be used as a routine test [13].
Problems found or anticipateddgaps in the knowledge base
Although prediction of antimicrobial resistance based on the
presence of a relatively limited number of acquired resistance
genes and chromosomal resistance-associated mutations might
give high sensitivity and speciﬁcity, the major challenge with
respect to both P. aeruginosa and A. baumannii lies in the identiﬁ-
cation or prediction of resistance due to chromosomal alterations
resulting in modiﬁcation of expression levels, particularly with
respect to efﬂux pumps, outer membrane proteins and intrinsic b-
lactamases. For instance, resistance to b-lactams in A. baumannii
can occur due to the insertion of elements such as ISAba1 and
ISAba125 upstream of the intrinsic b-lactamase genes blaADC and
blaOXA-51, increasing the expression of these genes and conse-
quently resistance to cephalosporins and carbapenems, respec-
tively [186,187]. Further, insertion sequence elements have been
implicated in disruption of genes encoding outer membrane pro-
teins that contribute to resistance, in particular to b-lactams [164].
Screening of genomes for insertion sequence elements in close
association with resistance-associated genes, as well as for gene
loss, will pose a signiﬁcant challenge.
For P. aeruginosa the challenge is expected to be even greater
due to the plethora of genes associatedwith intrinsic resistance and
alterations in these genes or regulatory genes can confer resistance
to several agents, even from different antimicrobial classes [179].
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might be required to achieve clinical resistance (e.g. combination of
decreased porin expression, increased efﬂux and/or increased b-
lactamase expression) [188]. Altered expression of genes could be
overcome by investigation of gene-expression analysis by RNA
sequencing. However, speciﬁc studies on P. aeruginosa indicate that
correlation between expression of genes on exposure to sub-MIC
concentrations of antimicrobial agents and the genes implicated
in intrinsic resistance is not always clearly observed [189].
Summary
In general these studies showed that prediction of resistance
based on the detection of known acquired resistance genes and
resistance-conferring mutations in antimicrobial targets can be
used to investigate the phenotypeegenotype relationship. How-
ever, additional comparative studies between phenotypic and
genotypic methods using representative strain collections of
P. aeruginosa and A. baumannii are required to evaluate the possi-
bility of conﬁdently predicting antimicrobial susceptibility/resis-
tance by WGS. Further, for both species a greater understanding of
the contribution to clinical resistance of alterations in intrinsic
resistance genes is required. This will require not only WGS, but
also knock-out and complementation studies of deleted/mutated
determinants.
The epidemiological implications of using WGS
The epidemiology of AMR is determined by the spread of the
host organisms harbouring resistance genes, and the spread of the
resistance genes by different routes of horizontal gene transfer.
Classical methodologies used to study the epidemiology of AMR
include strain genotyping with a variety of methods with a large
variation in reproducibility and discriminatory power. This includes
techniques such as multilocus sequence typing (MLST), pulsed ﬁeld
gel electrophoresis, variable number tandem repeat, multiple-locus
variable number tandem repeat analysis, ampliﬁed fragment length
polymorphism and Enterobacterial repetitive intergenic
consensus-based PCR [12]. Resistance genes can be identiﬁed by
micro-array approaches, PCR and sequence analysis. A variety of
molecular techniques are needed to identify and characterize
epidemiologically relevant mobile genetic elements involved in the
horizontal transfer of AMR genes, such as plasmids, conjugative
transposons or genomic islands. Dedicated PCRs and sequencing
are needed to identify the genetic environment of the AMR genes
such as integrons and/or transposons and insertion sequences, and
this is crucial to understand the epidemiological behaviour of
speciﬁc AMR genes [190].
PCR-based replicon typing ismost commonly applied for plasmid
characterization in Enterobacteriaceae. Relaxase typing is more
comprehensive and phylogenetically more informative, but is less
discriminatory within the Enterobacteriaceae, where there are major
concerns regarding resistance at present. Plasmid MLST and similar
techniques, such as Double Locus Sequence Typing or restriction
fragment length polymorphism, are used to sub-type plasmids. In
addition, toxin/anti-toxin systems encoded on plasmids in Entero-
bacteriaceaemay be key epidemiological determinants. As a result of
its complexity, plasmid epidemiology is currently beyond the ca-
pabilities of most clinical microbiology laboratories and is labour-
intensive even for the reference laboratory.
WGS opens a world of opportunities for enhanced (molecular)
epidemiology of AMR because, in principle, all essential information
needed to study the epidemiology of AMR will be available in the
sequences obtained.WGS is particularly effective for identifying and
characterizing clonal distribution of monomorphic species such as
S. aureus [55] andM. tuberculosis [191] and high-risk clones such asCTX-M-15-producing E. coli O25:H4-ST131 [192] or K. pneumoniae
carbapenemase-producing K. pneumoniae (e.g. ST11, 258 and 512)
[193]. Importantly, WGS provides high-resolution typing informa-
tion making most if not all of the traditional molecular typing ap-
proaches redundant. With its potential for an objective assessment
of the gene content, such as presence of absence of resistance genes
of particular public health importance, multicentre surveillance
approaches would greatly beneﬁt from the reporting of genomic
resistance markers, obviating the need to rely on phenotypic AST
proﬁles of doubtful inter-laboratory reproducibility.
However, WGS also has its weaknesses. For example, WGS is
weak in managing direct repeats and insertions in plasmids and
current bioinformatic cleaning often omits those from contigs. As a
result, short-read WGS data can be misleading if studying plasmid-
mediated outbreaks inwhich a broad host-range plasmid is moving
freely between different species, in each of which it has a different
phenotype.
To be able to analyse sequence output rapidly and identify all
information needed for epidemiology as listed above, the AMR
genes and plasmid types need to be determined in these sequences
using genomic databases such as RESFINDER or PLASMIDFINDER [194]. For
pMLST-typing, identiﬁcation of genomic islands, insertion se-
quences and transposons the genomic database PLACNET is available
[195]. In silico arrays or PCRs are also commonly applied but short-
read sequencing (e.g. as obtained with Illumina) is generally not
sufﬁcient to study the genetic environment of AMR genes.
Transfer (by transformation or conjugation) of a plasmid of in-
terest into a ‘workhorse’ bacterium with a known genetic back-
ground, with or without subsequent plasmid enrichment during
DNA extraction, will facilitate complete and correct plasmid
sequence assembly. Long-read or single-cell sequencing (e.g. by
PacBio or Oxford Nanopore) may be necessary [25,196], either alone
or as a ‘scaffold’ for high-coverage short-read data (e.g. Illumina).
However, both are beyond the capabilities of most clinical micro-
biology laboratories, and plasmid handling is relatively labour
intensive. This may still leave specialized annotation problems,
although direct annotation grammars can be helpful with these
[198,199].
Since different users may have different demands for WGS data,
a tiered approach can be applied.
Diagnostic information
(a) Rapid identiﬁcation of a targeted set of AMR genes may
provide important information at a clinical level. The output
could vary from answering a speciﬁc dichotomous question
(e.g. does a sample contain an ESBL-producer or an MRSA
isolate) to a more complete resistance/susceptibility proﬁle
[20,200,201]. The output should be based on the bacterial
species and the information required for the clinicians.
(b) The question of the positive and negative predictive values of
WGS will be important, although their usefulness will
depend on the targets to be identiﬁed, their diversity and
their prevalence in the gene pools [202,203].
Epidemiological information
(a) Identiﬁcation of genes and subtypes (e.g. blaCTX-M-15 versus
blaCTX-M-1, or blaCTX-M-3, or mecA versus mecC) may be
important for outbreak management, infection control or
even phylogeographic analysis.
(b) In silico strain typing in cultured organisms is based on:
 MLST (seven or more gene targets) for evolutionary
relatedness;
 Genomic islands such as SCCmec, SGI1, SXT;
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DNA rearrangements (e.g. for tracking outbreaks/ mapping
transmission chains).(c) In silico plasmid typing by mapping to a reference database
(in silico microarray)
 Sub-typing of plasmids by in silico PCR (pMLST, double
locus sequence typing, replicon sequence typing (RST))(d) Phylogenetic analysis of the total sequence output.
WGS approaches can be used to track markers from the chro-
mosome (e.g. MLST), from plasmids (e.g. incompatibility markers,
or post-segregational killing/toxin/antitoxin markers) and indi-
vidual genesdbarcoding to tie them together in individual isolates
by WGS using third-generation approaches such as PacBio or
Nanopore.
The ideal method will provide sufﬁcient depth and coverage to
answer all of these questions, but will vary with the starting ma-
terial: metagenomic approaches to DNA extracted directly from
clinical samples will require a considerably higher number of
sequencing reads than for analysis of a microorganism in pure
culture.
At the time of writing the availability of reference databases for
epidemiological questions remains limited both in the number of
species and typing methods that are represented. Further devel-
opment in this area will be crucial.
Clinical and wider impacts
The routine use of WGS in diagnostic and public health labo-
ratories holds the promise of a revolution in the identiﬁcation,
typing, antimicrobial susceptibility testing and determination of
pathogenicity of potential pathogens [104]. At present, at the
initiation of antimicrobial chemotherapy or thereafter when
deﬁnitive therapy is selected based on phenotypic AST, clinicians
have no routine data provided on the likely pathogenic potential of
any pathogens isolated. Future data from WGS linking pathoge-
nicity determinants to adverse clinical outcomes for certain highly
pathogenic strains may have signiﬁcant impacts on chemo-
therapydperhaps by identifying those at higher risk of infection-
related complications, those who may require more aggressive or
combination chemotherapy or prolonged intravenous courses of
antimicrobial agents. Conversely, reassurance that some potential
pathogens are of low pathogenicity may allow for shorter duration
therapy, oral therapy, less intensive patient monitoring, fewer in-
vestigations and perhaps earlier discharge. Such approaches are, at
present, almost entirely speculative but may have a greater clinical
impact than the work done so far on the value of WGS in predicting
phenotypic susceptibility or resistance when tested by conven-
tional methodologies.
At present, proof-of-principle studies have been completed for
WGS on common pathogens already isolated in pure cultures and
hence most data related to WGS for predicting antimicrobial sus-
ceptibility assume an initial culture step. This is an obvious limi-
tation in terms of speed of diagnosis compared with direct testing
of specimenmaterial. To date commonpathogens such as E. coli and
K. pneumoniae [14,19,21], S. aureus [46e49]; S. pneumoniae [64, 65]
and P. aeruginosa [180] have had WGS related to conventional
susceptibility with some success. In addition, there is also work to
show potential in Salmonella spp. [20], Acinetobacter spp. [13,181],
N. gonorrhoeae [88] and M. tuberculosis [122,155]. Although for
other organisms, including C. difﬁcile, little has been demonstrated
to date. Most work remains where there are signiﬁcant gaps in the
knowledge base regarding resistance mechanisms. However, at
present, we lack a clear understanding of how antimicrobial sus-
ceptibility data can be generated from WGS in a timely way forincorporation into clinical-care pathways and what the likely
clinical impacts will be. In particular, we do not fully understand
the barriers or facilitators to increased clinical use, assuming
technical problems can be overcome. The costs of routine delivery
of WGS data to predict AST have not been balanced against po-
tential ﬁnancial savings across the patient care pathway or the
clinical impacts. At present, even feasibility studies to start
answering these questions have not been reported.
One obvious potential advantage of WGS in AST is the increased
speed of information ﬂow even if at present WGS would depend on
an initial culture step. Increased speed of diagnosis has been iden-
tiﬁed as a way of improving antimicrobial stewardship and patient
outcomes. If WGS could be made to deliver pathogen identiﬁcation
and predict susceptibility for common pathogens within 8 hours of
initial culture it may offer enough to impact on measures of patient
outcome and use of antimicrobial agents to justify higher costs
within the laboratory. However, the longer it takes for data to
become available then the poorer the potential clinical impacts.
Thought needs to be given as to howWGS datawill be presented
to end-users. It is possible we will move from categorical reporting
of susceptible, intermediate or resistant to reporting the probability
of an isolate being susceptible or resistant based on pre-test
probabilities (perhaps different in different hospitals or different
areas within a hospital), the completeness of our genetic database
for a particular pathogen and the presence or absence of resistance
determinants as determined by WGS. We may even be able to give
measures of conﬁdence to these predictions. Such approaches will
require signiﬁcant staff education and evaluation as it is not clear
how prescribers would respond to such data.
As >95% of pathogen identiﬁcation and susceptibility testing in
present clinical microbiology laboratories is based on around 20
bacterial species and a limited number of antimicrobial agents it
may not be necessary to cover all possibilities to provide useful data
rapidly, but ratherwemight focus on a limited number of agents for
each pathogen initially and let more detailed data become available
later.
At present, the use of WGS outside reference or research labo-
ratories to determine antimicrobial susceptibility has not been
tested. Preliminary data are promising and feasibility studies need
to be conducted in amore clinical environment. It is likely thatWGS
will ﬁrst be used as a tool to predict antimicrobial susceptibility in
public-health microbiology laboratories in the coming years with
subsequent use closer to the patient to predict susceptibility in
pathogens such as M. tuberculosis before its wider application in
diagnostic laboratories.
Conclusions and recommendations
This EUCAST Subcommittee report on the role of WGS in AST of
bacteria has reviewed the state-of-theeart as a ﬁrst approach. It
refers to almost 200 published works and describes where we are
at the time of writing (late 2015 to early 2016). Despite the volume
of published literature already available we conclude that, at pre-
sent, there are insufﬁcient data to present a deﬁnitive document on
the topic. Instead, this report is intended to form a baseline dis-
cussion document, which can be revisited and updated at regular
intervals (probably every 18e24 months). This will be important as
sequencing technologies become more affordable and more widely
applied. This ﬁrst versionwill provide the baseline against which to
compare and assess future progress in the area.
We are aware of many ongoing, as yet unpublished, studies of
phenotypicegenotypic AST concordance and it is certain that the
amount of available data will increase in the near future. However,
the quality of those data needs to improve and to be assured via
more rigorous and ‘standardized’ approaches to data analysis.
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any microbiology laboratory, but it is important to appreciate that
the MIC or zone diameter measured reﬂects more than gene
presence/absence; these values reﬂect multiple and complex in-
terplays between different systems including cellular permeability,
inﬂux/efﬂux, target availability and binding, as well as enzymatic
expression levels and activities. So there are many challenges in
gathering and assessing evidence to consider whether AST can be
replaced by a genotypic method such as WGS, which does not
assess bacterial growth in the presence of antimicrobial agents.
At the present time, WGS-based analyses cannot yield an inferred
MIC or zone diameter. Hence the potential utility of WGS-based
approaches for AST must be considered at the level of detecting
gene presence or absence. We will need more powerful bioinfor-
matics tools in future if we seek to make inferences about antimi-
crobial susceptibility based on combinations of multiple different
genes or contributory mutations. Furthermore, WGS does not
directly provide information on levels of gene expression. Although
other technologies can do so, e.g. RNA sequencing, it seems unlikely
that these will ﬁnd a place in the clinical laboratory before WGS.
It is our recommendation that the primary AST comparator for
WGS-based prediction should be the ECOFF, wherever possible, to
assess WGS-inferred ‘antibiograms’ (based on gene positivity)
against phenotypically deﬁned categories of wild-type or non-wild-
type. Adoption of ECOFFs as the primary comparator would make
meta-analysis across different publications simpler, as comparison
of data would not be subject to confounding factors such as differ-
ences in breakpoints from different organizations. Nevertheless,
demonstrating concordance with interpretation based on clinical
breakpoints will ultimately be necessary for the use of WGS-based
testing to guide clinical decision making, but this will probably be
more difﬁcult to demonstrate for all organisms and antimicrobial
agents. For this reason, assessing WGS-derived data against clinical
breakpoints represents a tougher challenge, but should be encour-
aged as a secondary comparator and should ideally be done using
the same data sets that are used for ECOFF-based assessments.
The challenges of harmonizing antimicrobial susceptibility
breakpoints across multiple parallel and independent national and
international systems have been ongoing for >50 years, and we still
lack a globally harmonized system. When considering the intro-
duction of WGS-based approaches, we need to balance the needs of
clinical laboratories, where standardized and validated procedures
are required to meet accreditation standards, with the need for
intellectual and innovative academic challenge, which drives many
of those who generate bioinformatics tools. We recommend that
there should be international agreement on the most appropriate
and effective principles to facilitate early standardization and
harmonization of analytical approaches and interpretative criteria
for WGS-based predictive AST. However we also recommend at the
present time that we need to be pragmatic and must accept that
bioinformatics algorithms will vary. It is unrealistic to suggest a
single analytical approach. We recommend that different bioin-
formatics tools should perform to minimum standards and should
be calibrated and equivalent in terms of the results generated.
To facilitate such comparisons, we recommend that perfor-
mance of different bioinformatics tools should be calibrated against
a single database of all known resistance genes/mutations. There
have been efforts and investments in this direction, but multiple
solutions exist and are used, thereby confounding comparisons.
Establishing a single database will ensure that there is parity of
analysis and will facilitate measurement of comparative accuracies
across different systems. Such a global reference database would
need to be updated regularly, and must have strictly curated min-
imum standards for the inclusion of new resistance genes and
mutations. An important function of a centralized database wouldbe to control resistance gene nomenclature (since poor annotation
can confound current analyses, where multiple ‘hits’ from searches
may reﬂect inconsistent annotation of the same gene). The inclu-
sion criteria for any new determinant would probably need to be
set higher than those accepted for publication because strong evi-
dence of causal association would maximize the predictive values
of inferring AST phenotype from genotype.
The organisms considered in this report can be divided into three
main groups in terms of the available evidence for predicting AMR
using WGS. First, at present most is known for S. aureus and
M. tuberculosis and it is apparent that there is now momentum
behind their deeper investigation. For a second group of organisms,
including the Enterobacteriaceae (including Salmonella), initial studies
have shown promise, but serve to highlight, through poor concor-
dance, where gaps exist in the knowledge base about resistance
mechanisms either in some genera or species or for some agents. For
a third group of organisms, including S. pneumoniae, N. gonorrhoeae,
P. aeruginosa, A. baumannii and C. difﬁcile it is apparent that more
studies are required before we can even deﬁne the extent of the gaps
in the knowledge base accurately. More focused study and additional
funding resources are needed as a priority to improve knowledge for
the second and third of these groups.
Expansion of the knowledge base is a critical priority ifWGS is to
be considered seriously as a rival to phenotypic AST, better deﬁning
resistance determinants across all organisms. It seems likely that
WGS may replace phenotypic testing ‘soon’ for surveillance pur-
poses, where the low error rate has low impact. This would need to
be phased to reﬂect the evidence base for the organismeagent
being reported, and would require surveillance schemes to expand
their inclusion criteria to accept WGS-inferred data. In reference
laboratories,WGS-based ASTmay also be adopted ‘soon’, unless the
reason for investigation relates to individual patient management,
is for agents or species shown to have poor genotypicephenotypic
concordance, or is to assess the activity of novel agents.
Available published evidence does not currently support use of
WGS-inferred susceptibility to guide clinical decision making. Such
a paradigm shift would require large-scale education and behav-
ioural change among microbiologists and prescribers. Gene (or
mutation) absence cannot always reliably predict susceptibility, so
robust evidence will be needed to show that the potential of
genotypic tests for very major errors does not adversely impact on
treatment outcomes. It seems likely that this may ﬁrst be consid-
ered forM. tuberculosis, where the speed of WGS-generated results
offers advantage over traditional AST methods. However, even if
the evidence can be generated and expectations changed, for most
bacteria and in most countries the current cost and speed of
inferring antimicrobial susceptibility from WGS data remain pro-
hibitive to wide adoption in routine clinical laboratories. Never-
theless, as advances in the knowledge of polymorphisms associated
with antimicrobial resistance, technology, data sharing and training
become more widely available in high-burden countries,
sequencing technologies will be more attractive and cost effective
as the cost of goods comes down.
Finally, there may even be scope for WGS-based approaches to
be used to better understand and improve some areas of pheno-
typic AST. For some agents, there are technical challenges in
measuring susceptibility in any way that meaningfully correlates
with outcome. If WGS data could be correlated directly with
outcome, then this revolutionary tool might aid development of
improved criteria for interpreting phenotypic data.
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